However, while in C/EBP-β LIP-induced/CRT-wild-type tumors, doxorubicin strongly reduced tumor growth, the drug had significantly lower anti-tumor efficacy in C/EBP-β LIP-induced/KO-CRT tumors (Fig. 9d-e). Here, CALR is linked to neoplasm.